ENDPOINTS

EG 427 collects €27M in Series B to advance overactive bladder treatment

A French biotech focused on developing genetic medicines for neurological conditions has secured €27 million in a Series B raise to support its lead program through an early clinical trial. Paris-based EG 427 will use ...

Feb 20, 2025 - 12:55
 0
EG 427 collects €27M in Series B to advance overactive bladder treatment
A French biotech focused on developing genetic medicines for neurological conditions has secured €27 million in a Series B raise to support its lead program through an early clinical trial. Paris-based EG 427 will use ...
Read More

Tags:

Previous Article

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Next Article

‘Pokémon Go’ Maker Niantic Reportedly Selling Gaming Division, Shifting Focus to...

Related Posts

Ascletis’ obesity pill looks similar to Roche’s drug, early data suggest

Ascletis’ obesity pill looks similar to Roche’s drug, e...

Feb 19, 2025  0

States sue Trump administration over billions in NIH indirect cost cuts

States sue Trump administration over billions in NIH in...

Feb 10, 2025  0

Novo looks to recoup $830M from hypertension drug partner

Novo looks to recoup $830M from hypertension drug partner

Feb 18, 2025  0